Elite Pharmaceuticals, Inc. Expands Abuse Deterrent Technology Patent Portfolio Internationally

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NORTHVALE, N.J., March 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding the Company's abuse deterrent technology with the issuance of Canadian Patent Number 2,521,655 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent issuance expands the scope and reach of Elite's patent estate internationally. Elite has additional patents pending in the U.S., Canada and Europe.

Help employers find you! Check out all the jobs and post your resume.

Back to news